WVE-005 / Wave Life Sciences, Takeda - LARVOL DELTA

WVE-005, a stereopure antisense oligonucleotide for MAPT silencing in tauopathies (AAIC 2022) - No abstract available

MAPT

Wave Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire) - "Preclinical CNS programs in collaboration with Takeda: Multiple programs (including WVE-005) for central nervous system (CNS) indications: Wave is utilizing PN chemistry to design stereopure oligonucleotides for CNS indications, including Alzheimer’s disease, Parkinson’s disease and others, as part of its ongoing collaboration with Takeda. Wave continues to produce compelling in vivo data, including target engagement in the CNS of non-human primates, and progress multiple discovery programs towards portfolio entry and candidate nomination."

Preclinical • Alzheimer's Disease • CNS Disorders • Parkinson's Disease